A Phase 1 interventional study of Pemvidutide and Metformin in NASH - Nonalcoholic Steatohepatitis, sponsored by Altimmune, Inc.. Completed at 2 sites in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.
Sponsored by Altimmune, Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia — 8 open to participants now, 12 under way, 10 of them phase 3. Non-alcoholic Fatty Liver Disease · Australia.
Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, this one is the 49th largest by enrollment, is one of 11 that started in 2021, is one of 15 in phase 1, and was the 36th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →8 of the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia are open now. Recruiting first, the newest first:
Eccogene · Sites in Australia
Ages 18–65 · Healthy volunteers
GlaxoSmithKline · Sites in Australia, United States, France and 5 more countries
Ages 18–75
GlaxoSmithKline · Sites in Australia, United States, Canada and 6 more countries
Ages 18–75
Eli Lilly and Company · Sites in Australia, United States, Argentina and 31 more countries
Ages 18+
Akero Therapeutics, Inc · Sites in Australia, United States, Argentina and 20 more countries
Ages 18–80
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 23 · Phase 3 17
First in 2014; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 264 across the 54 interventional studies. Of the 40 that completed or were terminated, 24 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 54 have an industry lead sponsor. The 10 most frequent:
Altimmune, Inc. is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 4 (29%) have results posted.
Altimmune, Inc. has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Non-alcoholic Fatty Liver Disease with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07726368EccogeneStudy of ECC4703 With Sulfasalazine and Pitavastatin | 2026-12 |
| NCT07873229EccogeneDDI Study of ECC0509 With Metformin, Midazolam, and Caffeine | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Non-alcoholic Fatty Liver Disease with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, open-label, drug-drug interaction (DDI) study of pemvidutide (ALT-801) under steady state conditions on concomitantly administered medications in healthy subjects. The study will evaluate the effect of pemvidutide on the pharmacokinetics (PK) of metformin, warfarin, atorvastatin, digoxin, and the combined oral contraceptive (COC) ethinylestradiol/levonorgestrel. The study will be conducted in 3 parts, as described below. Each part will have 2 periods in a fixed sequence, where the first period is without pemvidutide administration and the second is with pemvidutide at steady state.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1, subjects received metformin 500 mg BID on Days 1 and 2, single doses of metformin 500 mg and atorvastatin 40 mg on Day 3, and a single dose of pemvidutide 0.6 mg on Day 8. In Period 2, subjects received single doses of pemvidutide1.2 mg on Day 15 and 1.8 mg on Days 22 and 29, metformin 500 mg BID on Days 34 and 35, and pemvidutide 1.8 mg on Day 36 immediately followed by oral metformin 500 mg and atorvastatin 40 mg.
Drug: Pemvidutide · Drug: Metformin · Drug: Atorvastatin
In Period 1, subjects received single doses of warfarin 10 mg and digoxin 500 mcg (0.5 mg) on Day 1, and a single dose of pemvidutide 0.6 mg on Day 8. In Period 2, subjects received single doses of pemvidutide 1.2 mg on Day 15 and 1.8 mg on Days 22 and 29, and pemvidutide1.8 mg immediately followed by warfarin 10 mg and digoxin 500 mcg (0.5 mg) on Day 36.
Drug: Pemvidutide · Drug: Warfarin · Drug: Digoxin
In Period 1, subjects received a combined oral contraceptive (COC) consisting of 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel once daily on Days 1 through 9 and a single dose of pemvidutide 0.6 mg on Day 15. In Period 2, subjects received single doses of pemvidutide 1.2 mg on Day 22 and 1.8 mg on Days 29 and 36. Subjects also received COC once daily on Days 35 through 42 and a single dose of pemvidutide 1.8 mg followed immediately by a single dose of COC on Day 43.
Drug: Pemvidutide · Drug: Ethinylestradiol and Levonorgestrel
Injected subcutaneously (SC)
Also known as: ALT-801
Taken by mouth (PO)
Taken by mouth (PO)
Taken by mouth (PO)
Taken by mouth (PO)
Drug pages: Ethinyl Estradiol · Levonorgestrel
Taken by mouth (PO)
Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801
Time frame: Baseline and Day 36
Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801
Time frame: Baseline and Day 43
Cmax and Tmax of metformin and atorvastatin/warfarin and digoxin
Time frame: Day 36
Cmax and Tmax of ethinylestradiol and levonorgestrel
Time frame: Day 43
The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to Day 77
Ran from Sep 2021 to primary completion in May 2022, 8 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is below that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemvidutide · Atorvastatin · Ethinyl Estradiol · Levonorgestrel
Non-alcoholic Fatty Liver Disease →
Altimmune, Inc.